Novo-Nordisk A/S
Market Cap
190B
Short interest (May 15)
0.5%
Net Short (Jun 03 ): 0.0%
Borrow Fee
0.25%
↓ 5.8%
Available Shares
10M
↓ 0.0%
Price Chart
Company Overview
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.